Skip to content
Review

Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease Beyond Fibrosis: Metabolic, Microbial, and Immune Determinants​.

Sep 2026 · Journal of Visualized Experiments · Vol 235 · 0 citations
Medicine

TL;DR

A narrative review evaluates what 'beyond fibrosis' should mean for risk assessment rather than treating fibrosis as dispensable and supports fibrosis-centered, layered risk stratification using clinical factors and noninvasive fibrosis measures.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is an increasingly important cause of hepatocellular carcinoma (HCC). Fibrosis and cirrhosis remain the best-validated predictors of HCC, yet a substantial minority of MASLD-related tumors are diagnosed without cirrhosis. This narrative review evaluates what 'beyond fibrosis' should mean for risk assessment rather than treating fibrosis as dispensable. We first separate the proportion of HCC cases that are noncirrhotic from the much lower absolute incidence of HCC in the noncirrhotic MASLD population. We then synthesize human, animal, and in vitro evidence for lipotoxic and oxidative injury, insulin and insulin-like growth factor signaling, gut-liver communication, and immune remodeling. We distinguish plausible mechanistic drivers from clinical risk modifiers, future-risk biomarkers, early detection tests, and disease-modifying interventions. Current evidence supports fibrosis-centered, layered risk stratification using clinical factors and noninvasive fibrosis measures, whereas genetic, proteomic, microbial, and immune markers remain investigational. Resmetirom and semaglutide improve MASH histology in selected noncirrhotic patients with F2-F3 fibrosis; evidence for direct HCC prevention by metabolic drugs or bariatric surgery remains observational or absent. Routine surveillance is not justified for MASLD without advanced fibrosis, but individualized evaluation in F3 disease and prospective validation of multivariable risk models are priorities.

View source

Similar papers

Review Sep 2026

Molecular mechanisms and pathogenesis of MASH

The state of the art of molecular and cellular mechanisms underlying MASH pathogenesis and its transition to hepatocellular carcinoma are highlighted.

S. Gallage, Olivier Govaere, Q. Anstee et al. · 3 citations
Review Open access Oct 2026

Beyond fibrosis: the molecular roadmap from MASLD to hepatocellular carcinoma

Metabolic dysfunction-associated steatotic liver disease (MASLD) has overtaken viral hepatitis as the fastest-growing cause of hepatocellular carcinoma (HCC) in most high-income countries. What makes this epidemic clinically treacherous is a feature that distinguishes MASLD-related HCC from other aetiologies: roughly h...

L. Nevi, A. Altomare, P. Gallo et al. · 1 citation
Review Open access Sep 2026

Chronic hepatitis C and metabolic dysfunction-associated steatotic liver disease: converging pathobiology, hepatocarcinogenesis, and clinical implications in the post-SVR era

New evidence indicates that hepatic steatosis before and after sustained virologic response (SVR) is associated with suboptimal fibrosis regression and persistent HCC risk, highlighting the need for integrated clinical management incorporating metabolic optimisation and individualised surveillance.

M. El-Kassas, Abeer Awad, K. Al-Naamani et al. · 0 citations
Review Open access Sep 2026

From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the most common chronic liver diseases worldwide, representing a major global health challenge closely linked to metabolic syndrome, obesity, and type 2 diabetes mellitus (TD2...

Damian Świerczek, Maja Dreger, Jakub Jatkowski et al. · 0 citations
Review Open access Sep 2026

Current Insights into Liver Fibrosis: Epidemiological Patterns, Etiopathogenesis, Clinical Correlates, and Research Agenda

Liver fibrosis is the common pathway through which chronic liver injury progresses to cirrhosis, portal hypertension, liver failure, hepatocellular carcinoma, and systemic complications. Its burden is increasing worldwide, driven mainly by metabolic dysfunction-associated steatotic liver disease, alcohol-related liver...

A. Lonardo, Mohamad Jamalinia, Ralf Weiskirchen · 0 citations
Open access Aug 2026

A new era in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): clinical breakthroughs and challenges

Promising histologic gains must now be translated into reduced morbidity and mortality through an ambitious agenda of long-term outcome trials, precision biomarkers, and equitable, multidisciplinary care models.

Zhi-Fu You, Ling-Long Yang, Yuan-Hao Long et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.